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tolerated. In an unselected patient population, this combi-
nation dose did not improve PFS. However, this combina-
tion showed a potential for improving efficacy of gefitinib 
in EGFR-mutant NSCLC (NCT01027676).
Keywords Gefitinib · Vorinostat · EGFR · NSCLC
Introduction
Epidermal growth factor receptor (EGFR)–tyrosine kinase 
inhibitors (TKIs) are now the therapy of choice for patients 
with EGFR-mutant non-small cell lung cancer (NSCLC). 
However, despite the initial response to EGFR-TKIs, most 
patients develop resistance and eventually relapse. The 
mechanisms responsible for acquired resistance to EGFR-
TKIs include secondary EGFR T790 M mutation, MET 
amplification, epithelial-to-mesenchymal transition (EMT) 
signature, histologic transformation to small cell lung can-
cer, and AXL kinase activation [1]. Furthermore, approxi-
mately 20 % of patients harboring sensitive EGFR muta-
tions exhibit a suboptimal response or primary resistance to 
EGFR-TKIs. In addition to the coexistence of other genetic 
alterations, such as PIK3CA or EGFR exon 20 insertion 
mutations, germline BIM deletion polymorphism has been 
reported as a possible mechanism of primary resistance to 
EGFR-TKIs [2]. Novel strategies to overcome the multi-
factorial resistance are needed to improve the efficacy of 
EGFR-TKIs, particularly in patients with EGFR mutations.
In addition, there is controversy regarding the use of 
EGFR-TKIs for patients with EGFR wild-type NSCLC. 
So far, EGFR-TKIs have been widely used for advanced 
NSCLC irrespective of the EGFR mutation status because 
earlier trials that demonstrated the efficacy of EGFR-TKIs 
for second- or third-line therapy of advanced NSCLC did 
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not consider EGFR genotype. However, recent randomized 
trials comparing erlotinib and docetaxel as a second-line 
therapy in EGFR wild-type NSCLC demonstrated the clear 
superiority of docetaxel over EGFR-TKIs in patients with 
EGFR wild-type NSCLC [3, 4]. Thus, further defining the 
subpopulation of EGFR wild-type NSCLC patients that is 
suitable for EGFR-TKIs therapy is needed.
Histone deacetylase inhibitors (HDACis) have emerged 
as promising multifunctional anticancer agents that regu-
late gene expression and transcription through chromatin 
remodeling. HDACis can also modulate a variety of cel-
lular functions, including growth, differentiation, and sur-
vival, through the acetylation of a wide range of proteins, 
including transcription factors, molecular chaperones, and 
structural components [5]. Recent data suggest that HDA-
Cis can increase sensitivity to EGFR-TKIs in lung can-
cer cells. HDACis can reverse resistance to EGFR-TKIs 
through induction of E-cadherin expression in lung cancer 
cells [6]. In addition, HDACis induce acetylation of Hsp90, 
resulting in reduced association of Hsp90 with key chaper-
one proteins, including EGFR, c-Src, STAT3, and Akt [7]. 
Furthermore, HDACis increase the expression of the proa-
poptotic BH3 domain-containing isoform of BIM, which 
restores the sensitivity to EGFR-TKIs [8]. Thus, current 
research on incorporating HDACis in NSCLC treatment is 
focused on the combination of HDACis with EGFR-TKIs 
[9].
Vorinostat is an inhibitor of class I and II histone dea-
cetylases that regulate the transcription of various genes 
involved in cell survival and apoptosis. Vorinostat has dem-
onstrated profound anti-growth activity against NSCLC 
cells [10]. Given the potential synergy between HDACis 
and EGFR-TKIs, we conducted a phase I/II study of gefi-
tinib and vorinostat in patients with advanced NSCLC.
Methods
Patients
The main eligibility criteria were histologic confirmation of 
advanced NSCLC, previous chemotherapy with at least one 
platinum-containing regimen, age ≥ 18 years, an Eastern 
Cooperative Oncology Group (ECOG) performance status 
(PS) of less or equal to 2, and a measurable disease accord-
ing to the Response Evaluation Criteria in Solid Tumors 
(RECIST). Adequate hematologic (WBC count ≥4,000/
mm3, platelet count ≥150,000/mm3), hepatic (bilirubin 
level ≤1.5 mg/dL, AST/ALT ≤80 IU/L), and renal (cre-
atinine concentration ≤1.5 mg/dL) function was required. 
Patients with brain metastases were enrolled if they were 
clinically stable without steroid treatment. The exclusion 
criteria included serious concomitant systemic diseases or a 
history of uncontrolled cardiac dysfunction, or any previous 
treatment with EGFR signaling inhibitors or HDAC inhibi-
tors. The protocol was approved by an independent ethics 
committee/institutional review board and was conducted in 
accordance with the Declaration of Helsinki, Good Clinical 
Practice. Each patient provided written informed consent.
Study design
The phase I study was a standard 3 + 3 dose-escalation 
design, followed by a phase II part. The primary endpoint 
of the phase I part was to determine the maximum tolerated 
dose (MTD) and the recommended phase II dose (RP2D) 
of vorinostat in combination with gefitinib. The primary 
endpoint of phase II part was progression-frees survival. In 
the phase I study, three patients were treated per cohort for 
one cycle (28 days per cycle). Dose-limiting toxicity (DLT) 
was defined as any grade 3 or 4 non-hematologic toxicity 
(except nausea or vomiting that responds to symptomatic 
therapy, fatigue that responds to maximal management 
and alopecia) or any grade 4 hematologic toxicity occur-
ring during the first cycle. Toxicity was graded according 
to the National Cancer Institute Common Toxicity Criteria 
of Adverse Events (CTCAE) version 4.0. In the absence 
of any DLT, three patients were treated in the subsequent 
cohort. The presence of DLT in a cohort required that 
another three patients be treated in the cohort for one cycle. 
If no DLTs occurred, then dose escalation continued. RP2D 
was defined as the highest dosage at which one of six 
patients at most experienced a DLT. No intra-patient dose 
escalation was permitted.
Treatment delivery
All patients received once-daily oral doses of 250 mg gefi-
tinib on days 1–28 in combination with vorinostat on days 
1–7 and days 15–21 of each 28 days cycle. Up to three dose 
levels of vorinostat were evaluated (200, 300, and 400 mg/
day). During phase II, vorinostat was administered at the 
RP2D of 400 mg/day. Study treatment continued until dis-
ease progression (PD) or until another termination crite-
rion was met: unacceptable toxicity, consent withdrawal, 
loss to follow-up, death, major protocol violation, or 
noncompliance.
Study assessment
Safety assessment included history, physical examinations, 
vital signs, ECOG PS, adverse events (AEs), electrocardi-
ography (ECG), blood chemistry, and hematology. Safety 
assessments were performed at screening, biweekly (days 1 
and 15) during cycles one and two, on day 1 of subsequent 
cycles, and during the final study visit.
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Baseline computed tomography (CT) scans of the chest 
and abdomen, bone scintigraphy, and brain magnetic reso-
nance imaging or CT were obtained within 4 weeks before 
initiation of treatment. Efficacy variables, including progres-
sion-free survival (PFS) and overall survival (OS), were eval-
uated during phase II. Tumor response was assessed using 
RECIST 1.1 [11] after every two cycles of therapy.
EGFR and KRAS mutation analysis
Genomic DNA was extracted from 10 % neutral formalin-
fixed, paraffin-embedded (FFPE) tumor tissue blocks using 
the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). 
We analyzed EGFR and KRAS mutations using the poly-
merase chain reaction (PCR)-based direct DNA sequencing 
method [12].
Genotyping of BIM deletion polymorphism (BIM DEL)
We obtained blood samples before treatment. We extracted 
genomic DNA from patients’ peripheral blood and geno-
typed the deletion by a single PCR reaction using the prim-
ers 5′-ccaccaatggaaaaggttca-3′ and 5′-gcctgaaggtgctgaga-
aag-3′ and Hotstartaq DNA Polymerase (Qiagen) with the 
following thermo-cycling conditions: 94 °C for 15 min, 
(94 °C for 15 s, 60 °C for 30 s, and 68 °C for 5 min) × 35, 
and 68 °C for 10 min. The resulting PCR products from the 
deletion (970 bp) and the wild-type (3,873 bp) alleles were 
analyzed on 1.5 % agarose gels. We performed two sepa-
rate PCR reactions to determine the presence of the wild-
type and deletion alleles.
Immunohistochemistry for E-cadherin and vimentin
Samples with E-cadherin (Zymed, CA, USA) and vimentin 
(Ventana, AZ, USA) immunohistochemistry staining inten-
sity scores of 0 or +1 (<50 % of the cells have complete 
circumferential membrane staining at a low intensity) were 
classified as negative. Those with +2 or +3 (≥50 % of the 
cells have complete circumferential membrane staining at a 
high intensity) were classified as positive.
Statistical analysis
The primary object of the phase I study was to determine 
the MTD of vorinostat in combination with the standard 
dose of gefitinib. The last six patients enrolled into the 
phase I study were included in the analysis of the phase 
II study. The primary endpoint of the phase II component 
was to reject the null hypothesis (median PFS, 3.5 months) 
and to accept the alternative hypothesis (median PFS, 
6.5 months). To test the hypothesis and to calculate the 
sample size, we assumed an exponential distribution. Thus, 
the estimated 6-month PFS under the null hypothesis and 
alternative hypothesis were 0.305 and 0.530, respectively. 
To achieve a power of .80, with α = .05, we calculated a 
sample size of 40 patients. Anticipating a 10 % dropout 
rate, the samples size for the phase II portion totaled 44 
patients.
All tests of hypotheses were conducted at a two-sided 
α = 0.05 level. The log-rank test was used to compare 
PFS and OS time according to mutation status. The distri-
bution of PFS and OS were estimated using the Kaplan–
Meier method. Statistical comparison of the response rates 
according to the mutation status was performed using Chi-
squared or Fisher’s exact test.
Results
Patient characteristics
Between July 2010 and June 2013, 52 patients were 
enrolled in this study. The patient characteristics are sum-
marized in Table 1. All patients had stage IV disease, and 
most of the patients exhibited good PS and adenocarcinoma 
histology. Thirty-six patients received the study treatment 
as second-line therapy. The most common reason for study 
discontinuation was disease progression (45 of 52: 86.5 %).
Phase I study results
The toxicities encountered during the phase I study are 
summarized in Table 2. Three patients were enrolled in 
the level 1 treatment, and none experienced DLT. Three 
patients were enrolled in the level 2 treatment, and one 
experienced DLT due to grade 3 hyperglycemia. Conse-
quently, another three patients were enrolled in the level 2 
treatment, and none experienced DLT. In the level 3 treat-
ment group, the initial three patients experienced no DLT. 
Thus, the level 3 group was expanded up to six patients, 
and one experienced DLT due to grade 3 anorexia. The 
RP2D was determined to be biweekly 400 mg/day vori-
nostat in combination with daily 250 mg gefitinib (level 3).
Phase II study
The following analysis is based on 43 patients, including 
six patients who were treated during the MTD of the phase 
I portion and 37 patients who were treated during the phase 
II portion of this study. The follow-up data were frozen on 
March 3, 2014. The median follow-up was 16.2 months 
(95 % CI 13.2 to 19.3 months). The median number of 
cycles was two (range 1–24 cycles).
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Response and survival
Among 43 patients, there were 16 patients with a partial 
response (37.2 %), 6 with stable disease (14.0 %), and 
21 with progressive diseases (48.8 %). The median PFS 
was 3.2 months (95 % CI 2.3 to 4.1 months). The median 
OS was 19.0 months (95 % CI 17.2 to 20.8 months). The 
response and PFS data are presented in Fig. 1a, b.
Toxicity
Toxicity was assessable in all 43 patients (Table 3). The 
most frequent grade 3 toxicities were anorexia (11.6 %), 
diarrhea (9.3 %), fatigue (7.0 %), and anemia (4.7 %). 
There was no grade 4 hematologic toxicity. There was no 
treatment-related death or irreversible toxicity that was 
considered to be related to the treatment in this study.
Table 1  Patient characteristics
a
 NOS, sarcomatoid carcinoma
b
 One patient had concurrent EGFR exon 19 deletion with A871T and KRAS G12S mutations: This patient is regarded as KRAS mutation posi-
tive
Phase I Phase II
Level 1 Level 2 Level 3
N 3 6 6 37
Median age (range) 67 (65–76) 63.5 (59–71) 52.5 (44–66) 56 (39–79)
Male/female 2/1 3/3 2/4 21/16
Stage IIIB/IV 0/3 0/6 0/6 0/37
ECOG performance status 0/1/2 0/3/0 1/2/3 2/4/0 5/25/7
Histology, adenocarcinoma/squamous/othera 3/0/0 4/2/0 5/1/0 32/3/2
Sensitive EGFR mutation, positive/negative/unknown 1/2/0 4/2/0 4/2/0 13/23/0
K-RAS mutation, positive/negative/unknown 1/0/2 1/4/1 0/6/0 3b/34/0
BIM deletion polymorphism, positive/negative 1/2 1/5 1/5 4/33
Prior chemotherapy regimen, one/two 2/1 3/3 5/1 26/11
Table 2  Toxicities in phase 1 
(n = 15) Level 1 (n = 3) Level 2 (n = 6) Level 3 (n = 6)
Grade 1 2 3 4 1 2 3 4 1 2 3 4
Anemia 2 1 0 0 2 1 0 0 1 1 0 0
Blood bilirubin increased 0 0 0 0 1 0 0 0 1 0 0 0
Creatinine increased 0 0 0 0 2 0 0 0 0 0 0 0
Hyperglycemia 1 1 0 0 2 0 1 0 1 0 0 0
Neutrophil count decreased 0 0 0 0 0 0 0 0 0 1 0 0
Platelet count decreased 0 0 0 0 1 0 0 0 1 0 0 0
White blood cell count decreased 0 0 0 0 0 0 0 0 3 0 0 0
Anorexia 1 0 0 0 2 0 0 0 2 1 1 0
Diarrhea 0 0 0 0 4 0 0 0 5 1 0 0
Dry mouth 0 0 0 0 1 0 0 0 1 0 0 0
Dry skin 0 0 0 0 2 0 0 0 2 0 0 0
Fatigue 1 0 0 0 3 0 0 0 1 0 0 0
Oral mucositis 0 0 0 0 2 0 0 0 4 1 0 0
Nausea 1 0 0 0 1 0 0 0 3 0 1 0
Papulopustular rash 0 0 0 0 0 0 0 0 1 0 0 0
Pruritus 0 0 0 0 3 0 0 0 4 0 0 0
Acneiform rash 0 0 0 0 1 0 0 0 1 0 0 0
Maculopapular rash 0 0 0 0 3 0 0 0 3 0 0 0
Nasal mucositis 0 0 0 0 0 0 0 0 1 0 0 0
Vomiting 0 0 0 0 1 0 0 0 2 0 0 0









e: sensitive EGFR mutations
k: KRAS codon 12 mutations
k+: concurrent KRAS G12S & EGFR 19Del, A871 mutations
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Fig. 1  Efficacy. a Waterfall plot of response. b Progression-free survival PR partial response; SD stable disease; PD progressive disease; e sensi-
tive EGFR mutations; k KRAS codon 12 mutations; BIM Del BIM deletion polymorphism
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Exploratory biomarker analysis
We analyzed EGFR and KRAS mutations, as well as 
BIM DEL, and E-cadherin and vimentin expression in all 
patients. Of the 52 patients enrolled in this study, 22 exhib-
ited sensitive EGFR mutations (sixteen exon 19 deletions, 
five L858R mutations, and one R776H mutation) and five 
exhibited KRAS mutations (three G12C and two G12S 
mutations). One patient with KRAS G12S exhibited a 
concurrent EGFR exon 19 deletion and A871T mutation. 
This case was classified as KRAS mutation positive. BIM 
DEL was observed in seven patients. Immunohistochemis-
try was available in 43 patients, and eighteen and nineteen 
patients exhibited positive E-cadherin and vimentin expres-
sion, respectively. The response and survival data accord-
ing to biomarkers are summarized in Table 4. The pres-
ence of sensitive EGFR mutations was predictive of higher 
response rates (RR) and longer PFS and OS compared with 
patients with KRAS mutations or patients without either 
mutation (Fig. 2a, b). Patients harboring BIM DEL muta-
tions exhibited a trend toward higher RR and longer PFS; 
however, the trend failed to achieve statistical significance 
(Fig. 2c, d). E-cadherin and vimentin expression was not 
associated with RR or survival (Fig. 2e–h).
Discussion
Our study demonstrated that gefitinib administered daily 
at a dose of 250 mg with biweekly vorinostat at a dose of 
400 mg/day was feasible and well tolerated. However, the 
efficacy results measured by PFS do not support this com-
bination for molecularly unselected NSCLC patients. Nev-
ertheless, it is noteworthy that patients harboring sensitive 
EGFR mutations achieved a remarkable RR of 77 % and a 
median PFS of 9.1 months even in the second- or third-line 
setting, results that are comparable to the first-line use of 
gefitinib in EGFR-mutant NSCLC.
Thus far, four randomized phase III studies have dem-
onstrated superior RR and PFS with first-line use of gefi-
tinib over platinum-based chemotherapy in EGFR-mutant 
NSCLC. First-line gefitinib in EGFR-mutant NSCLC 
yields consistent RR of 70–80 % and a median PFS of 
9–10 months [13–16]. To date, there are no direct compar-
isons between first-line versus second-line use of EGFR-
TKIs in EGFR-mutant NSCLC. Although the sequence of 
EGFR-TKIs in EGFR-mutant NSCLC may not affect the 
OS [17], the tumor response rates to second-line EGFR-
TKIs are usually lower than to first-line use. Maemondo 
et al. [15] documented that the RR to gefitinib was slightly 
worse in the second-line setting compared with the first-
line setting (58.5 vs. 73.7 %) in a randomized phase III 
study. Sugio et al. [18] also reported that the RR to gefi-
tinib was lower in the second-line setting compared with 
the first-line setting (50.0 vs. 77.8 %). In a randomized 
phase III study that compared gefitinib with docetaxel as 
a second- or third-line therapy, the gefitinib arm demon-
strated a RR of 42.1 % and a median PFS of 7.0 months 
in EGFR-mutant patients [19]. Although there was no 
Table 3  Toxicities in phase II (n = 43)
Grade %
1 2 3 4 Grade 3/4 (total)
Diarrhea 19 12 4 0 9.3 (81.4)
Anorexia 12 14 5 0 11.6 (72.1)
Pruritus 21 5 0 0 0 (60.5)
Acneiform rash 16 10 0 0 0 (60.5)
Hyperglycemia 19 4 0 0 0 (53.5)
Anemia 12 8 2 0 4.7 (51.2)
Vomiting 13 6 1 0 2.3 (46.5)
Nausea 13 4 1 0 2.3 (41.9)
Fatigue 12 2 3 0 7.0 (39.5)
Oral mucositis 12 2 0 0 0 (32.6)
White blood cell count decreased 12 0 0 0 0 (27.9)
Dry skin 10 1 0 0 0 (25.6)
Hypocalcemia 8 2 0 0 0 (23.3)
ALP increased 9 1 0 0 0 (23.3)
Platelet count decreased 9 0 1 0 2.3 (23.3)
Creatinine increased 10 0 0 0 0 (23.3)
ALT increased 6 2 1 0 2.3 (20.9)
AST increased 6 2 0 0 0 (18.6)
Weight loss 4 4 0 0 0 (18.6)
Headache 4 4 0 0 0 (18.6)
Blood bilirubin increased 5 2 0 0 0 (16.3)
Hyponatremia 6 0 1 0 2.3 (16.3)
Electrocardiogram QT corrected 
interval prolonged
6 0 0 0 0 (14.0)
Maculopapular rash 6 0 0 0 0 5 (14.0)
Epigastric pain 0 6 0 0 0 (14.0)
Abdominal pain 2 1 3 0 7.0 (14.0)
Hypophosphatemia 0 5 1 0 2.3 (14.0)
Hypokalemia 5 0 1 0 2.3 (14.0)
Constipation 4 1 0 0 0 (11.6)
Peripheral sensory neuropathy 4 1 0 0 0 (11.6)
LDH increased 5 0 0 0 0 (11.6)
Hypermagnesemia 0 0 3 0 7.0 (7.0)
Neutrophil count decreased 0 4 0 0 0 (9.3)
Dizziness 2 1 1 0 2.3 (9.3)
Nasal mucositis 3 1 0 0 0 (9.3)
Paronychia 1 0 1 0 2.3 (4.7)
Dehydration 0 0 1 0 2.3 (2.3)
Hand foot syndrome 0 1 0 0 0 (2.3)
Acute renal failure 0 0 1 0 2.3 (2.3)
481Cancer Chemother Pharmacol (2015) 75:475–483 
1 3
significant difference in the OS treatment effect, the OS 
in EGFR-mutant NSCLC was 14.2 months with gefi-
tinib [19]. Some data suggest that the relatively inferior 
response to second-line EGFR-TKIs may result from the 
decreased abundance of EGFR-mutant tumor cells after 
chemotherapy [20, 21].
It is clear that EGFR-TKIs are most active in EGFR-
mutant NSCLC. The sensitive EGFR mutations target the 
TK domain that is essential for the phosphorylation func-
tion, which results in enhanced kinase activity and also in 
increased sensitivity to EGFR-TKIs [22]. A recent experi-
mental study revealed that vorinostat treatment increased 
the acetylation of EGFR, which leads to enhanced EGFR 
phosphorylation in cancer cells. Additionally, combination 
therapy effectively inhibited cell growth in vitro compared 
with individual therapy [23]. Despite second- or third-line 
use of gefitinib in our study, the relatively higher RR and 
longer survival times observed in EGFR-mutant NSCLC 
may be attributed to the combination with vorinostat. Vori-
nostat-induced acetylation-enhanced tyrosine kinase phos-
phorylation of EGFR may overcome or delay the develop-
ment of acquired resistance to gefitinib caused by the low 
abundance of EGFR-mutant cancer cells. By contrast, the 
efficacy observed in patients with wild-type EGFR was 
similar to other reports. Accordingly, vorinostat in com-
bination with gefitinib may be more effective for patients 
with EGFR-mutant NSCLC. At the time of the study ini-
tiation, EGFR mutation test was not routinely performed 
in Korea and gefitinib was usually used as second- or 
third-line therapy. Thus, we enrolled non-molecularly 
selected patients.
Very recently, Reguart et al. [24]. reported a phase I/II 
study of vorinostat and erlotinib for EGFR-mutant NSCLC 
after erlotinib progression. The authors found no meaning-
ful activity in the erlotinib-resistant population. Given that 
the most common cause of acquired resistance to EGFR-
TKIs in EGFR-mutant NSCLC is T790 M mutation, vori-
nostat may be not sufficient to overcome T790 M-related 
resistance to EGFR-TKIs. Witta et al. [25] reported a ran-
domized phase II trial of erlotinib with or without enti-
nostat, an isoform-selective HDACis, in previously treated 
NSCLC. The authors also failed to demonstrate improved 
outcomes. Nevertheless, the authors reported that high 
E-cadherin expression was predictive of longer OS with 
the combination therapy. However, biomarker analysis was 
available in only a subset of patients, and more patients 
enrolled in the combination arm were EGFR FISH posi-
tive. Thus, the impact of E-cadherin expression on HDA-
Cis in combination with erlotinib remains unclear. We also 
analyzed E-cadherin expression. Furthermore, we added 
vimentin expression to further define cases with an epi-
thelial phenotype. However, we did not observe any sig-
nificant association with efficacy. We also analyzed the pre-
dictive role of BIM DEL. BIM DEL has been reported to 
be associated with intrinsic resistance to EGFR-TKIs due 
to the impaired generation of BIM with the proapoptotic 
BH3 domain [2]. However, vorinostat can upregulate the 
expression of BIM protein with BH3 domain, which restore 
Table 4  Exploratory biomarker analysis
pos positive, neg negative, NA not assessable, PFS progression-free survival, OS overall survival, CI confidence interval
* Chi-square or Fisher’s exact test, ≠ Kaplan–Meier test
EGFR/KRAS mutation BIM deletion polymorphism E-cadherin Vimentin
EGFR pos KRAS pos Both neg Pos Neg Pos Neg Pos Neg
N 22 5 25 7 45 18 25 19 24
Response
 PR 17 0 3 5 15 9 7 7 9
 SD 3 1 4 0 8 2 5 4 3
 PD 2 3 18 2 21 7 12 7 12
 NA 0 1 0 0 1 0 1 1 0
 P* <0.0001 0.247 0.426 0.541
PFS, months
 Median 9.1 1.8 1.8 9.2 3.6 3.6 3.6 5.4 2.1
 95 % CI 7.4–10.8 NA 1.7–1.9 0.0–18.7 1.2–6.0 0.7–6.7 0.5–6.7 2.4–8.4 1.1–3.1
 P ≠ 0.004 0.486 0.842 0.125
OS, months
 Median 24.1 7.3 11.4 24.1 19.0 19.0 20.3 18.5 20.3
 95 % CI NA 3.7–11.0 0.0–23.1 6.7–41.5 17.0–21.0 15.5–22.5 8.1–32.5 10.8–26.2 16.5–24.1
 P ≠ 0.017 0.561 0.843 0.812











































































































Fig. 2  Progression-free and overall survival according to EGFR and KRAS mutation status (a, b), BIM deletion polymorphism (c, d), E-cad-
herin expression (e, f), and vimentin expression (g, h), respectively
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sensitivity to gefitinib in EGFR-mutant NSCLC cells with 
BIM DEL [8]. Patients with BIM DEL exhibited a trend 
toward longer PFS compared with those without BIM DEL. 
However, only seven (13 %) of 52 patients exhibited BIM 
DEL; thus, the impact of vorinostat in combination with 
gefitinib in this population should be investigated further.
The combination therapy of vorinostat and gefitinib as 
second- or third-line therapy did not improve outcomes in 
an unselected patient population. Nevertheless, the planned 
biomarker analysis suggests that this combination may be 
effective for EGFR-mutant NSCLC by enhancing EGFR 
phosphorylation. Although further study is required to 
confirm the usefulness of vorinostat in combination with 
gefitinib in EGFR-mutant NSCLC, our study suggests the 
potential benefit of vorinostat for improving the efficacy of 
EGFR-TKIs in EGFR-mutant NSCLC.
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